by Karen O'Hanlon Cohrt | Dec 26, 2023 | Disease Models
It’s a fibroblast-like cell adorned with long cytoplasmic processes that wrap around the endothelial cells in blood vessels, it controls blood flow through the blood vessels, and it is essential for normal brain function and development. Which cell type is it? Well,...
by Karen O'Hanlon Cohrt | Nov 21, 2023 | Industry News, Trends
Antibody drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. In contrast to conventional chemotherapies, which do not discriminate between healthy and cancerous cells, ADCs are...
by Karen O'Hanlon Cohrt | Sep 24, 2023 | Disease Models
In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy....
by Karen O'Hanlon Cohrt | Jul 18, 2023 | Disease Models
The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets, and screen...
by Karen O'Hanlon Cohrt | Apr 4, 2023 | Disease Models
This article was originally published on 4th April 2023. It was revised and republished on 19th March 2023, to reflect important updates in the NASH therapeutic development space, including FDA approval of Rezdiffra in March 2024. Welcome to our new mini-series about...
